UBS Group’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-293,502
| Closed | -$41.1K | – | 10361 |
|
|
2024
Q1 | $41.1K | Buy |
293,502
+281,287
| +2,303% | +$55.4K | ﹤0.01% | 6598 |
|
|
2023
Q4 | $1.77K | Buy |
+12,215
| New | +$1.9K | ﹤0.01% | 8225 |
|
|
2023
Q3 | – | Sell |
-8,368
| Closed | -$26.1K | – | 10154 |
|
|
2023
Q2 | $26.1K | Buy |
+8,368
| New | +$24.9K | ﹤0.01% | 6763 |
|
|
2022
Q2 | – | Sell |
-6,200
| Closed | -$15K | – | 11198 |
|
|
2022
Q1 | $15K | Buy |
6,200
+122
| +2% | +$318 | ﹤0.01% | 7865 |
|
|
2021
Q4 | $28K | Buy |
+6,078
| New | +$20.1K | ﹤0.01% | 7467 |
|
|
2021
Q3 | – | Sell |
-284
| Closed | -$3K | – | 10260 |
|
|
2021
Q2 | $3K | Sell |
284
-4,065
| -93% | -$33K | ﹤0.01% | 8859 |
|
|
2021
Q1 | $38K | Buy |
4,349
+2,393
| +122% | +$26.3K | ﹤0.01% | 6809 |
|
|
2020
Q4 | $20K | Buy |
1,956
+1,162
| +146% | +$12.7K | ﹤0.01% | 6960 |
|
|
2020
Q3 | $7K | Sell |
794
-2,110
| -73% | -$16.7K | ﹤0.01% | 7155 |
|
|
2020
Q2 | $21K | Buy |
2,904
+1,899
| +189% | +$20.2K | ﹤0.01% | 6532 |
|
|
2020
Q1 | $10K | Sell |
1,005
-2,384
| -70% | -$30.7K | ﹤0.01% | 6944 |
|
|
2019
Q4 | $45K | Buy |
+3,389
| New | +$41.3K | ﹤0.01% | 6414 |
|
Other funds holding GRTX
UBS Group's GRTX Position: Q2 2024 in Review
UBS Group sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 293,502 shares — an estimated $41.1K sold.
UBS Group first reported a position in GRTX in Q4 2019 and held it in 12 quarters. The position peaked at $45K in Q4 2019. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- UBS Group reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 293,502 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $41.1K.
- UBS Group first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
- UBS Group's Galera Therapeutics, Inc. Common Stock position peaked at $45K in Q4 2019.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.